{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:10:13Z","timestamp":1749183013112,"version":"3.41.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>This article describes drugs used in primary care that could alter patients' risk for and severity of COVID-19. The risks and benefits of each drug class were differentiated according to the strength of evidence from 58 selected randomized controlled trials, systematic reviews, and meta-analyses. Most of the studies reported on drugs affecting the renin-angiotensin-aldosterone system. Other classes included opioids, acid suppressants, nonsteroidal anti-inflammatory drugs, corticosteroids, vitamins, biguanides, and statins. Current evidence has not fully differentiated drugs that may increase risk versus benefits in COVID-19 infection. Further studies are needed in this area.<\/jats:p>","DOI":"10.1097\/01.jaa.0000918768.11544.e5","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T17:00:57Z","timestamp":1682442057000},"page":"28-33","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Drugs in primary care that may alter COVID-19 risk and severity"],"prefix":"10.1097","volume":"36","author":[{"given":"Brent","family":"Luu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sampath","family":"Wijesinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrick","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rynee","family":"Wijesinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leianna","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Kayingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijid.2020.12.077","article-title":"Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis","volume":"104","author":"Liu","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"R2-20250605","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/j.gastro.2020.09.028","article-title":"Effect of acid suppressants on the risk of COVID-19: a propensity score-matched study using UK Biobank","volume":"160","author":"Fan","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"R3-20250605","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1053\/j.gastro.2021.02.028","article-title":"Lack of consistent associations between pharmacologic gastric acid suppression and adverse outcomes in patients with coronavirus disease 2019: meta-analysis of observational studies","volume":"160","author":"Kamal","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"R4-20250605","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/myc.13256","article-title":"The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis","volume":"64","author":"Ahmadikia","year":"2021","journal-title":"Mycoses"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41392-021-00521-7","article-title":"Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Ma","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/head.13903","article-title":"COVID-19 and headache medicine: a narrative review of non-steroidal anti-inflammatory drug (NSAID) and corticosteroid use","volume":"60","author":"Arca","year":"2020","journal-title":"Headache"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijid.2021.05.016","article-title":"Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: a systematic review and meta-analysis of adjusted effect estimates","volume":"108","author":"Martha","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amjcard.2020.12.073","article-title":"Meta-analysis of the effect of aspirin on mortality in COVID-19","volume":"142","author":"Salah","year":"2021","journal-title":"Am J Cardiol"},{"issue":"4","key":"R9-20250605","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/acer.14573","article-title":"Network meta-analysis on the mechanisms underlying alcohol augmentation of COVID-19 pathologies","volume":"45","author":"Huang","year":"2021","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13011-021-00395-6","article-title":"The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review","volume":"16","author":"Alexander","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"16","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2020.17477","article-title":"Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic","volume":"324","author":"Ochalek","year":"2020","journal-title":"JAMA"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"108176","DOI":"10.1016\/j.drugalcdep.2020.108176","article-title":"Signal of increased opioid overdose during COVID-19 from emergency medical services data","volume":"214","author":"Slavova","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"R13-20250605","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s11524-020-00486-y","article-title":"Opioid overdose-related emergency department visits and accidental deaths during the COVID-19 pandemic","volume":"97","author":"Rodda","year":"2020","journal-title":"J Urban Health"},{"issue":"3","key":"R14-20250605","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.14514","article-title":"The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections","volume":"87","author":"Vaja","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/HYPERTENSIONAHA.120.15989","article-title":"Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis","volume":"76","author":"Chan","year":"2020","journal-title":"Hypertension"},{"issue":"10","key":"R16-20250605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients","volume":"22","author":"Baral","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"R17-20250605","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/jcpt.13246","article-title":"Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis","volume":"45","author":"Barochiner","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"R18-20250605","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/HJH.0000000000002784","article-title":"Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies","volume":"39","author":"Bavishi","year":"2021","journal-title":"J Hypertens"},{"issue":"1","key":"R19-20250605","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1038\/s41598-021-84678-9","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis","volume":"11","author":"Biswas","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"R20-20250605","doi-asserted-by":"crossref","first-page":"563","DOI":"10.11622\/smedj.2020159","article-title":"Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis","volume":"62","author":"Cai","year":"2021","journal-title":"Singapore Med J"},{"key":"R21-20250605","first-page":"100627","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis","volume":"31","author":"Caldeira","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"R22-20250605","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1111\/bcp.14660","article-title":"Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: systematic review and meta-analysis","volume":"87","author":"Chu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"R23-20250605","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"609857","DOI":"10.3389\/fcvm.2021.609857","article-title":"Associations between the use of renin-angiotensin system inhibitors and the risks of severe COVID-19 and mortality in COVID-19 patients with hypertension: a meta-analysis of observational studies","volume":"8","author":"Dai","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"R25-20250605","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"7","author":"Grover","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"R26-20250605","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"issue":"12","key":"R27-20250605","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/imj.15002","article-title":"Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis","volume":"50","author":"Koshy","year":"2020","journal-title":"Intern Med J"},{"issue":"5","key":"R28-20250605","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/thoraxjnl-2020-215322","article-title":"Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis","volume":"76","author":"Lee","year":"2021","journal-title":"Thorax"},{"journal-title":"Clin Cardiol","article-title":"Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis","author":"Liu","key":"R29-20250605"},{"issue":"12","key":"R30-20250605","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/14779072.2020.1826308","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"18","author":"Lo","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"R31-20250605","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"R32-20250605","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/M20-1515","article-title":"Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review","volume":"173","author":"Mackey","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"R33-20250605","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0036933020949219","article-title":"Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19","volume":"65","author":"Megaly","year":"2020","journal-title":"Scott Med J"},{"issue":"2","key":"R34-20250605","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2020.05.052","article-title":"Estimation of renin-angiotensin-aldosterone-system (RAAS) inhibitor effect on COVID-19 outcome: a meta-analysis","volume":"81","author":"Pirola","year":"2020","journal-title":"J Infect"},{"issue":"5","key":"R35-20250605","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jjcc.2020.10.015","article-title":"Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis","volume":"77","author":"Ren","year":"2021","journal-title":"J Cardiol"},{"issue":"2","key":"R36-20250605","doi-asserted-by":"crossref","first-page":"e001353","DOI":"10.1136\/openhrt-2020-001353","article-title":"Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis","volume":"7","author":"Ssentongo","year":"2020","journal-title":"Open Heart"},{"key":"R37-20250605","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijcard.2020.07.041","article-title":"Systematic review of the role of renin-angiotensin system inhibitors in late studies on COVID-19: a new challenge overcome","volume":"321","author":"Volpe","year":"2020","journal-title":"Int J Cardiol"},{"issue":"3","key":"R38-20250605","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/jmv.26625","article-title":"The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis","volume":"93","author":"Wang","year":"2021","journal-title":"J Med Virol"},{"issue":"11","key":"R39-20250605","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1093\/cid\/ciaa1592","article-title":"The effect of prior angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment on coronavirus disease 2019 (COVID-19) susceptibility and outcome: a systematic review and meta-analysis","volume":"72","author":"Xu","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"R40-20250605","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/jmv.26588","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: meta-analysis","volume":"93","author":"Yokoyama","year":"2021","journal-title":"J Med Virol"},{"issue":"4","key":"R41-20250605","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/jmv.26695","article-title":"Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: a meta-analysis","volume":"93","author":"Zhang","year":"2021","journal-title":"J Med Virol"},{"key":"R42-20250605","doi-asserted-by":"crossref","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"issue":"8","key":"R43-20250605","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/jcph.1852","article-title":"The interplay between the immune system, the renin-angiotensin-aldosterone system (RAAS), and RAAS inhibitors may modulate the outcome of COVID-19: a systematic review","volume":"61","author":"Naveed","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"R44-20250605","doi-asserted-by":"crossref","first-page":"e003176","DOI":"10.1136\/bmjgh-2020-003176","article-title":"Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis","volume":"6","author":"Abioye","year":"2021","journal-title":"BMJ Glob Health"},{"key":"R45-20250605","doi-asserted-by":"crossref","first-page":"660420","DOI":"10.3389\/fnut.2021.660420","article-title":"Low serum 25-hydroxyvitamin D (vitamin D) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis","volume":"8","author":"Akbar","year":"2021","journal-title":"Front Nutr"},{"issue":"4","key":"R46-20250605","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/nu13041339","article-title":"Relation between vitamin D and COVID-19 in aged people: a systematic review","volume":"13","author":"Dram\u00e9","year":"2021","journal-title":"Nutrients"},{"issue":"2","key":"R47-20250605","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.7861\/clinmed.2021-0035","article-title":"Perspective: vitamin D supplementation prevents rickets and acute respiratory infections when given as daily maintenance but not as intermittent bolus: implications for COVID-19","volume":"21","author":"Griffin","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"R48-20250605","doi-asserted-by":"crossref","first-page":"e043737","DOI":"10.1136\/bmjopen-2020-043737","article-title":"Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes: a systematic review","volume":"11","author":"Grove","year":"2021","journal-title":"BMJ Open"},{"key":"R49-20250605","article-title":"Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials","author":"Jolliffe","year":"2020","journal-title":"medRxiv"},{"issue":"11","key":"R50-20250605","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2020.26848","article-title":"Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial","volume":"325","author":"Murai","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"R51-20250605","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40618-021-01614-4","article-title":"Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis","volume":"45","author":"Pal","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"R52-20250605","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/qjmed\/hcab009","article-title":"Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis","volume":"114","author":"Shah","year":"2021","journal-title":"QJM"},{"issue":"1","key":"R53-20250605","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40001-021-00490-1","article-title":"Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial","volume":"26","author":"JamaliMoghadamSiahkali","year":"2021","journal-title":"Eur J Med Res"},{"issue":"2","key":"R54-20250605","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jmv.26498","article-title":"Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis","volume":"93","author":"Kow","year":"2021","journal-title":"J Med Virol"},{"key":"R55-20250605","doi-asserted-by":"crossref","first-page":"704666","DOI":"10.3389\/fmed.2021.704666","article-title":"Metformin in patients with COVID-19: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"R56-20250605","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.dsx.2020.11.006","article-title":"The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis","volume":"14","author":"Lukito","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"R57-20250605","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40256-021-00490-w","article-title":"The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"22","author":"Kow","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"R58-20250605","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0040-1722307","article-title":"Protective effects of statins administration in European and North American patients Infected with COVID-19: a meta-analysis","volume":"47","author":"Onorato","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"R59-20250605","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s43440-021-00233-3","article-title":"In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis","volume":"73","author":"Permana","year":"2021","journal-title":"Pharmacol Rep"},{"issue":"1","key":"R60-20250605","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/07853890.2021.1933165","article-title":"The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis","volume":"53","author":"Wu","year":"2021","journal-title":"Ann Med"},{"issue":"7","key":"R61-20250605","doi-asserted-by":"crossref","first-page":"ofab284","DOI":"10.1093\/ofid\/ofab284","article-title":"Prior statin use and risk of mortality and severe disease from coronavirus disease 2019: a systematic review and meta-analysis","volume":"8","author":"Yetmar","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000918768.11544.e5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:04:57Z","timestamp":1749153897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000918768.11544.e5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000918768.11544.e5","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}